scholarly journals The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States

2021 ◽  
Author(s):  
Robin K. Dore ◽  
Jenya N. Antonova ◽  
Chakkarin Burudpakdee ◽  
Lawrence Chang ◽  
Magdaliz Gorritz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Venous Thromboembolism ◽  
Cardiovascular Events ◽  
The United States ◽  
Major Adverse Cardiovascular Events ◽  
Treatment History ◽  
Incidence Prevalence

scholarly journals Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Gabriela Bittencourt Gonzalez Mosegui ◽  
Fernando Antõnanzas ◽  
Cid Manso de Mello Vianna ◽  
Paula Rojas
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Latin American ◽  
United States Of America ◽  
Purchasing Power Parity ◽  
The United States ◽  
Power Parity ◽  
Drug Prices ◽  
The Us ◽  
Latin American Countries

Abstract Background The objective of this paper is to analyze the prices of biological drugs in the treatment of Rheumatoid Arthritis (RA) in three Latin American countries (Brazil, Colombia and Mexico), as well as in Spain and the United States of America (US), from the point of market entry of biosimilars. Methods We analyzed products authorized for commercialization in the last 20 years, in Brazil, Colombia, and Mexico, comparing them to the United States of America (USA) and Spain. For this analysis, we sought the prices and registries of drugs marketed between 1999 and October 1, 2019, in the regulatory agencies’ databases. The pricing between countries was based on purchasing power parity (PPP). Results The US authorized the commercialization of 13 distinct biologicals and four biosimilars in the period. Spain and Brazil marketed 14 biopharmaceuticals for RA, ten original, four biosimilars. Colombia and Mexico have authorized three biosimilars in addition to the ten biological ones. For biological drug prices, the US is the most expensive country. Spain’s price behavior seems intermediate when compared to the three LA countries. Brazil has the highest LA prices, followed by Mexico and Colombia, which has the lowest prices. Spain has the lowest values in PPP, compared to LA countries, while the US has the highest prices. Conclusion The economic effort that LA countries make to access these medicines is much higher than the US and Spain. The use of the PPP ensured a better understanding of the actual access to these inputs in the countries analyzed.

scholarly journals Cardiovascular Outcomes in Patients With Mitochondrial Disease in the United States: A Propensity Score Analysis

2021 ◽  
Vol 48 (3) ◽  
Author(s):  
Tran Nguyen ◽  
Talal Alzahrani ◽  
Joseph Krepp ◽  
Gurusher Panjrath
Keyword(s):  
Heart Failure ◽  
Mitochondrial Disease ◽  
Cardiovascular Events ◽  
Propensity Score Analysis ◽  
Genetic Disorders ◽  
Systolic Heart Failure ◽  
The United States ◽  
Major Adverse Cardiovascular Events ◽  
Hospital Death ◽  
Wide Range

Mitochondrial disease comprises a wide range of genetic disorders caused by mitochondrial dysfunction. Its rarity, however, has limited the ability to assess its effects on clinical outcomes. To evaluate this relationship, we collected data from the 2016 National Inpatient Sample, which includes data from >7 million hospital stays. We identified 705 patients (mean age, 22 ± 20.7 yr; 54.2% female; 67.4% white) whose records included the ICD-10-CM code E88.4. We also identified a propensity-matched cohort of 705 patients without mitochondrial disease to examine the effect of mitochondrial disease on major adverse cardiovascular events, including all-cause in-hospital death, cardiac arrest, and acute congestive heart failure. Patients with mitochondrial disease were at significantly greater risk of major adverse cardiovascular events (odds ratio [OR]=2.42; 95% CI, 1.29–4.57; P=0.005), systolic heart failure (OR=2.37; 95% CI, 1.08–5.22; P=0.027), and all-cause in-hospital death (OR=14.22; 95% CI, 1.87–108.45; P<0.001). These findings suggest that mitochondrial disease significantly increases the risk of inpatient major adverse cardiovascular events.

scholarly journals 98 Non-specific chest pain hospital admissions and readmissions for serious cardiovascular events in the United States

2019 ◽  
Author(s):  
Shing Kwok ◽  
David Brown ◽  
Harriette Van Spall ◽  
Mary Norine Walsh ◽  
Aditya Bharadwaj ◽  
...  
Keyword(s):  
United States ◽  
Chest Pain ◽  
Cardiovascular Events ◽  
Hospital Admissions ◽  
The United States
Sign in / Sign up

Export Citation Format

Share Document